Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

Amgen Drops Repatha List Price 60% To Cut Medicare Co-Pays And Boost Use

24 Oct 2018
News

Mandy Jackson @ScripMandy Mandy.Jackson@informausa.com

Executive Summary

Company says 75% of Medicare Part D patients who aren't eligible for low income subsidies abandon the PCSK9 inhibitor at the pharmacy counter due to $370 co-pay, which may now range from $25-$150 per dose.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

United States

Related Companies

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

Pricing Strategies Market Access Medicare

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS124137

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS124137

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Amgen Drops Repatha List Price 60% To Cut Medicare Co-Pays And Boost Use

News

Executive Summary

Related Content

Teva Stands By Migraine Strategy After Ajovy Misses Boat On Express Scripts Deal

Lilly Looks To Emgality Access, Injector And Data To Differentiate Its CGRP Inhibitor

Gilead Lowering HCV Drug List Prices With Authorized Generics

Harper, Hooper Exit As Amgen Revenues Rise

Express Scripts Pushing Manufacturers To Lower List Prices By Offering Cheaper Brand Alternatives

Trump Tries To Shame A Defiant Pfizer On Drug Pricing

Amgen's Aimovig Aims To Capture As Many Migraine Patients As Possible With $6,900 Price

Topics

Related Companies

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert